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Degradation of tritiated Leu-enkephalin was studied in cultures of primary astrocytes from rat brain. The 
incubation experiments with a cell suspension revealed Tyr as the main tritiated metabolite; however, 
Tyr-Gly-Gly and Tyr-Gly were detectable as well. Using a crude membrane preparation of the 
astrocytes, we found about equal amounts of Tyr and Tyr-Gly-Gly but only trace quantities of Tyr-Gly. 
The production of Tyr was completely inhibited by bestatin, an inhibitor of aminopeptidases, that of 
Tyr-Gly-Gly by thiorphan, a specific inhibitor of enkephalinase A. The results prove the ability of glial 
cells to degrade enkephalin by aminopeptidase and a membrane-bound enkephalinase A. 
Primary astrocyte Leu-enkephalin Aminopeptidase Enkephalinase A 
1. INTRODUCTION 2. MATERIALS AND METHODS 
Soon after identification of the enkephalins, 
numerous authors showed that aminopeptidases 
present in the brain and in a variety of peripheral 
tissues are able to degrade these pentapeptides 
[l-5]. Enkephalinase A, a dipeptidylpeptidase ac- 
tivity present in crude membrane fractions of rat 
brains, which generates the tyrosine-glycine-- 
glycine (Tyr-Gly-Gly) fragment from enkephalin, 
was reported in [6,7]. This enzyme appears to have 
the specificity of a physiologically relevant 
enkephalinase. The discovery of thiorphan as a 
reasonably specific inhibitor of enkephalinase A 
[8] permits a more thorough evaluation of the im- 
portance of this enzyme for the degradation of ex- 
ogenous enkephalin. 
Tyrosyl-[3H]Leu-enkephalin was obtained from 
New England Nuclear (Dreieich), all amino acids, 
peptides and bestatin from Sigma Chemical (Mtin- 
then). Captopril was a gift of Heyden (Munchen). 
Thiorphan was kindly donated by Professor B.P. 
Roques (Departement de Chimie Organique, 
UniversitC RenC Descartes, Paris). 
2.1. CeN culture 
Studies on neuroblastoma cells (N4TGl) [9] and 
cultured human endothelial cells [IO] demonstrate 
that these cells are also able to degrade enkephalins 
effectively. However, only aminopeptidase activi- 
ty, which cleaves the Tyr-Gly amide bond, was 
detected in these studies. Our investigations on 
glial cells in culture show that enkephalin degrada- 
tion appears to result from the action of 
aminopeptidase, enkephalinase A and a Tyr-Gly 
producing mechanism. 
Primary glial cultures of 2-day-old rats were 
cultured as in [ll] with a slight modification [12]. 
The dissociated cells were grown in 150 cm’ plastic 
flasks at 37OC under a humidified atmosphere of 
5% CO2 and 95% air. The medium, which con- 
tained 20% and after 10 days 10% fetal calf serum, 
was changed twice a week and the experiments 
were performed with the suspended cells during the 
third week of cultivation. Cultures usually were 
observed by phase contrast or differential in- 
terference contrast (DIK) microscopy. 
2.2. Incubation experiments 
Cells, grown as monolayers, were cautiously 
scraped off and centrifuged at 150 x g for 10 min. 
They were washed thrice with Krebs-Ringer-Tris 
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(KRT) buffer (pH 7.4) containing NaCl (128 mM), 
CaCl2 (1.4 mM), MgC12 (1.4 mM), KC1 (5 mM), 
Tris-HCl (20 mM) and D-glucose (5 mM). In 
some experiments we prepared a crude membrane 
fraction according to [13]. The cells or the crude 
membranes were finally suspended in KRT buffer 
(- 1 mg protein/ml suspension). Protein was deter- 
mined by the Lowry method [ 141. The suspension 
(40~1) was incubated with 120 nM [3H]Leu- 
enkephalin (20 ~1) and 40 ,J KRT buffer. The reac- 
tion was terminated by adding 10~1 0.8 M HCl 
and freezing in liquid nitrogen. When the influence 
of drugs like bestatin, captopril or thiorphan was 
studied, the KRT buffer was replaced by the drug 
solution made in buffer. 
2.3. Analysis of the degradation products 
by HPLC 
HPLC was carried out with a Gynkotek con- 
stant flow pump (model 600/200). Generally, 20 ~1 
samples were injected with a 50~1 Hamilton syr- 
inge through a stop flow injector (model 
Rheodyne). The initial flow rate was 1.0 ml/min 
and was increased to 2.0 ml/min after 4 min. The 
3H-labeled products were identified by their coelu- 
tion with unlabeled standards, which were detected 
spectrophotometrically at 254 nm. For conve- 
nience, we used two isocratic systems instead of a 
gradient. The first isocratic system was used to 
separate Tyr, Tyr-Gly-Gly and Tyr-Gly, while 
Tyr-Gly-Gly-Phe and Leu-enkephalin were 
separated by the second one. The mobile phase had 
the following composition: 
First system: citrate-phosphate buffer (0.01 M + 
0.3 mM 1-octanesulfonic acid sodium salt 
monohydrate) : methanol (90: 10) pH 3; 
Second system: phosphate buffer (0.1 M, pH 
6.0) : methanol (65 : 35). 
The column (stainless steel, 12.5 cm length, 
4.1 mm i.d.) was packed by the slurry technique 
with reversed phase material (Hypersil ODS Shan- 
don, mean particle size 5 pm). First we eluted with 
system 1; after 6.8 min we used system 2. A chro- 
matographic run was terminated after 13 min. 
Retention times of the metabolites were: Tyr 
4 min, Tyr-Gly-Gly 6 min, Tyr-Gly 7 min, 
Tyr-Gly-Gly-Phe 9.5 min and Leu-enkephalin 
94 
12 min. After each chromatographic run methanol 
(2 ml/min, 10 min) and the mobile phase system 1 
(4 ml/min, 15 min) had to percolate through the 
column. 
3. RESULTS 
3.1. Hydrolysis of Leu-enkephalin by primary 
astrocytes in suspension 
The rates of enkephalin degradation by primary 
astrocytes in suspension at 0°C and 25°C are 
shown in fig.1. At 25”C, a 70% degradation is 
observed within 30 min. This enzymatic process is 
almost inactive at 0°C. Analysis of the degradation 
products performed after incubation of [3H]Leu- 
enkephalin with the cell suspension, yields four 
radioactive peaks with retention times closely cor- 
responding to those of Tyr, Tyr-Gly-Gly, 
Tyr-Gly and Leu-enkephalin. Fig.2 shows the 
curves representing the time-dependent formation 
of [3H]Tyr, [3H]Tyr-Gly-Gly and [3H]Tyr-Gly. 
We found a very low level of the breakdown pro- 
ducts Tyr-Gly-Gly and Tyr-Gly as compared to 
the main metabolite Tyr. For example, after 6 min 
-30% of Leu-enkephalin was degraded. Of the 
degraded enkephalin 77% was accounted for by 
Tyr formation, 8% by Tyr-Gly and 15% by 
Tyr-Gly-Gly formation. 
25’C 
i 
$ 40. 
6 
% 
d 
20. 
o”c 
0 3 6 10 . 15 min 
Fig.1. Time course of enkephalin degradation at 0°C 
and 25°C: 40~1 cell suspension (1 pg protein/l ,~l) were 
incubated at 0°C and 25°C in 100~1 KRT buffer (pH 
7.4) containing 120 nM [3H]Leu-enkephalin. Enzyme 
activity was measured as in section 2. Mean values of 5 
expts f SD. 
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Fig.2. Time course of the formation of Tyr, Tyr-Gly 
and Tyr-Gly-Gly by enkephalin degradation at 25°C. 
Incubation was performed with the cell suspension 
(- - -) and with the crude membrane fraction (-) 
under the same conditions as mentioned in fig. 1. Mean 
values of 5 expts f SD. 
3.2. Hydrolysis of Leu-enkephalin by crude 
membranes of primary astrocytes 
Proceeding on the postulation that a specific 
peptidase involved in the control of enkephalin 
concentration in the synaptic cleft ought to be 
membrane-bound, we used the crude membrane 
fraction to study the enkephalin breakdown. In 
this case, we found approximately equal amounts 
of Tyr and Tyr-Gly-Gly, but only trace quantities 
of Tyr-Gly (based on mg protein at 25°C) (fig.2). 
3.3. Effects of inhibitors on Leu-enkephalin 
degradation by crude membranes of primary 
astrocytes 
We used three inhibitors for further 
characterization of the enkephalin degradation 
pathways. Bestatin shows a concentration- 
dependent inhibition of Tyr formation. Only the 
highest concentration (10e4 M) of the inhibitor 
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Fig.3. Influence of inhibitors on the formation of the 
Tyr-containing metabolites. The crude membranes were 
preincubated with the inhibitors for 15 min and then 
incubated in 100,A KRT buffer (pH 7.4) containing 
120 nM [‘H]Leu-enkephalin for 6 min at 25°C. 
Influence of thiorphan, bestatin and captopril on: (a) the 
Tyr-formation; (b) the Tyr-Gly-Gly formation; (c) the 
Tyr-Gly production. Mean values of 5 expts + SD. 
reduced the Tyr-Gly-Gly production. The 
Tyr-Gly formation seemed to be increased slightly 
in the presence of bestatin. Thiorphan (over 
1O-s-1O-6 M) h as no effect on Tyr and Tyr-Gly 
formation, whereas it decreases the tripeptide pro- 
duction dramatically. Captopril (10-7-10-5 M) 
was ineffective in all cases (fig.3). 
4. DISCUSSION 
In respect o the method used, this study shows 
a clear-cut separation of all possible Tyr contain- 
ing breakdown products of the pentapeptide Leu- 
enkephalin with the help of HPLC. Another 
HPLC method has been described [15] which uses 
ligand exchange chromatography to separate all 
the possible breakdown products of enkephalin. 
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Our method using ion-exchange chromatography 
allows the separation of the metabolites Tyr, 
Tyr-Gly and Tyr-Gly-Gly with one isocratic 
system. 
The brain peptides Leu-enkephalin and Met- 
enkephalin bind to opiate receptors and are 
thought to act as neurotransmitters in processes 
related to pain [ 16-181. Several enkephalin 
degrading enzyme activities are known to be pre- 
sent in the brain: a soluble aminopeptidase cleaves 
the Tyr-Gly bond of enkephalin [1,15], a par- 
ticulate endopeptidase (enkephalinase A) which 
hydrolyzes the Gly-Phe bond [6,15] and 
enkephalinase B, which cleaves the Gly-Gly bond 
[19]. However, their relative contribution to the 
regulation of enkephalin levels and in the termina- 
tion of synaptic events has not yet been established 
[1,6,19-211. 
The incubation experiments with primary 
astrocytes in suspension revealed Tyr as the main 
metabolite. If a crude membrane preparation of 
these glial cells is used, one finds a pronounced 
decrease in the specific activity of Tyr. This might 
be due to the removal of the Tyr producing en- 
zyme, presumed to be associated with membranes, 
during the membrane preparation. Furthermore, it 
could not be excluded that some cells in the suspen- 
sion are not intact. In this case, a part of the Tyr 
producing enzyme activity might be of intracellular 
origin. However, results with astrocytes grown on 
glass cover slides, which were neither scraped off 
nor suspended, demonstrate the same specific ac- 
tivity of the Tyr-producing enzyme as compared 
with a cell suspension (not shown). 
Wagner and Dixon [22] examined 8 protease in- 
hibitors of microbiological origin and found that 
bestatin was a potent inhibitor of a rat brain 
enkephalin aminopeptidase. The inhibitory effect 
of bestatin on Tyr formation of primary astrocytes 
observed in our experiments suggested that the 
cleavage of the Tyr-Gly bond is catalyzed by an 
aminopeptidase. 
In respect o the Tyr-Gly formation we can only 
say that the enzyme probably involved is 
membrane-associated, not membrane-bound, 
similar to the Tyr producing aminopeptidase. 
Tyr-Gly formation in our experiments is probably 
not a product of the enkephalinase B reaction [19] 
as it is insensitive to p-chloromercuribenzoate. 
Furthermore, the existence of a Tyr-Gly produc- 
96 
ing dipeptidylaminopeptidase [23] is unlikely, 
because this enzyme is inhibited by o- 
phenanthrolin, a drug which was ineffective on 
primary astrocytes. Our special interest pertains to 
the formation of Tyr-Gly-Gly. Besides the par- 
ticulate enkephalinase A [6], angiotensin- 
converting enzyme (ACE, EC 3.4.15.1, kininase 
II) [24,25] could also contribute to enkephalin 
degradation. Enkephalinase A and ACE are en- 
dopeptidases or dipeptidyl carboxypeptidases, 
which split the Gly-Phe bond. The use of selective 
inhibitors of enkephalinase A such as thiorphan 
[8], and of ACE such as captopril might, 
therefore, aid in evaluating the relative contribu- 
tion of these enzymes to enkephalin degradation. 
The Tyr-Gly-Gly producing enzyme is 
membrane-bound. Its specific activity in the mem- 
brane preparation is -2-3-fold that of the cell 
suspension. Thiorphan over 10-8-10-6 M, 
decreases the tripeptide production dramatically, 
whereas it has no effect on Tyr and Tyr-Gly pro- 
duction. However, captopril ( 10e7- lo-‘M) was in- 
effective in all cases. 
From the observations that primary astrocytes 
show Tyr-Gly-Gly formation during enkephalin 
degradation, that this formation exhibits a very 
high sensitivity to thiorphan and that the other in- 
hibitors used (except bestatin 10e4 M) have no in- 
fluence on the production of this metabolite, we 
conclude that glial cells possess enkephalinase A. 
Due to the results obtained with the crude mem- 
brane fraction, we assume the localization of this 
enzyme to be mainly on cell membranes. 
It is very interesting that the glial cells are able 
to degrade enkephalin so efficiently. There might 
be some doubts as to the validity of the conclusion 
that enkephalinase A is situated on neuronal mem- 
branes as these experiments have been conducted 
on synaptosome preparations [6,26,27] and a con- 
tamination with glial cells cannot be excluded. 
However, further experiments are being conducted 
with neurons and neuron-like cells to investigate 
the presence of enkephalinase on the neuronal 
membrane. 
The role of the glial cells as a site of enkephalin 
degradation can at present only be a target of 
speculation. The putative biological relevance of 
this enzymatic process could depend on the lack of 
both enkephalins and their receptors on the glial 
cells. The presence of enkephalins in astrocytes is 
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presently being studied. To the best of our 
knowledge, no enkephalin receptors have as yet 
been located on astrocytes. Miller et al. [28] found 
no enkephalin receptors on C 6 glioma cells. The 
enkephalins can be more or less specifically 
degraded by a series of enzymes. If we assume that 
various types of cells possess such mechanisms in 
their synaptic regions, then the extracellular 
enkephalin concentration would be kept at a 
minimum. Thus, our results fit well in the general 
concept that one of the functions of glial cells is the 
prevention of the spread of neural (e.g., 
enkephalinergic) impulses into improper channels 
or target sites. 
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